Chapter 16.Vortioxetine
Sections
Excerpt
Vortioxetine, formerly designated Lu AA 21004, was developed by Lundbeck in an attempt to add to a selective serotonin (5-hydroxytryptamine [5-HT]) reuptake inhibitor (SSRI) additional properties, namely, 5-HT1A and 5-HT3 receptor affinities (Bang-Andersen et al. 2011). These pharmacological targets were based on the premises that the antidepressant effect of SSRIs can be enhanced by combining them with a partial 5-HT1A agonist and that 5-HT3 antagonists are antiemetic drugs, nausea being a common side effect of SSRIs (Sanchez et al. 2015). In 2013, vortioxetine, marketed under the brand name Brintellix, received approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of major depressive disorder (Takeda Pharmaceuticals America 2016). In the United States, at the behest of the FDA, the brand name was subsequently changed to Trintellix to avoid confusion with the anticoagulant drug Brilinta (ticagrelor).
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
